Insider Selling: OPKO Health (NASDAQ:OPK) Director Sells $16,698.50 in Stock

OPKO Health, Inc. (NASDAQ:OPK) Director John Paganelli sold 9,175 shares of OPKO Health stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1.82, for a total value of $16,698.50. Following the sale, the director directly owned 389,914 shares of the company’s stock, valued at $709,643.48. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

OPKO Health Stock Performance

Shares of NASDAQ:OPK traded down $0.02 during midday trading on Thursday, reaching $1.75. The company’s stock had a trading volume of 9,785,748 shares, compared to its average volume of 3,240,198. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $1.58 and a 200 day moving average of $1.35. OPKO Health, Inc. has a twelve month low of $0.98 and a twelve month high of $1.83. The firm has a market capitalization of $1.31 billion, a PE ratio of -19.44 and a beta of 1.52.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The firm had revenue of $130.83 million during the quarter, compared to analysts’ expectations of $136.62 million. During the same period in the previous year, the business posted $0.03 EPS. The business’s revenue was down 56.9% compared to the same quarter last year. On average, equities analysts expect that OPKO Health, Inc. will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in OPKO Health during the second quarter worth about $55,468,000. AWM Investment Company Inc. acquired a new stake in shares of OPKO Health during the second quarter worth about $3,165,000. Bank of New York Mellon Corp purchased a new position in shares of OPKO Health in the second quarter valued at approximately $1,995,000. Bank of America Corp DE purchased a new position in shares of OPKO Health in the second quarter valued at approximately $1,194,000. Finally, First Trust Advisors LP acquired a new position in shares of OPKO Health in the first quarter valued at approximately $570,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health News Summary

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could bolster liquidity as OPKO concentrates on its biotech business. OPKO third-quarter results and business highlights
• Positive Sentiment: OPKO’s reported third-quarter loss was $0.05 per share, better than the $0.07 loss analysts expected, according to one estimate. Zacks report on OPKO’s third-quarter results
• Neutral Sentiment: Following the sale agreement, OPKO forecast 2026 revenue from continuing operations of $268 million to $278 million. OPKO’s 2026 continuing-operations revenue outlook
• Negative Sentiment: Reported third-quarter revenue of $65.4 million was well below FactSet’s $136.6 million estimate, although the earnings-call summary characterized revenue as up 16%. Comparisons may reflect the changing business mix following the planned BioReference sale. Q3 revenue report
• Negative Sentiment: Investors also face biotech execution risk: the earnings-call coverage said losses widened and the CAR-T program timeline was delayed, potentially postponing progress on a key part of OPKO’s future growth strategy. Q3 earnings-call highlights

Analyst Upgrades and Downgrades

OPK has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. UBS Group set a $4.00 price objective on shares of OPKO Health in a research note on Friday, October 16th. Piper Sandler reissued an “overweight” rating and issued a $4.00 target price (up from $3.00) on shares of OPKO Health in a research note on Friday, October 16th. Barrington Research upgraded OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 target price on the stock in a report on Friday, October 16th. Finally, HC Wainwright restated a “buy” rating on shares of OPKO Health in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.42.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.